<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Interstitial lung disease associated with Sjögren's disease: Management and prognosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Interstitial lung disease associated with Sjögren's disease: Management and prognosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Interstitial lung disease associated with Sjögren's disease: Management and prognosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carlos Roberto Ribeiro de Carvalho, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ronaldo A Kairalla, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bruno Guedes Baldi, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joyce S Lee, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 22, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H17660313"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Sjögren's disease (SjD) is a chronic inflammatory disorder characterized by diminished lacrimal and salivary gland function and associated with lymphocytic infiltration of exocrine glands, especially the lacrimal and salivary glands. Respiratory complications of SjD include airway mucosal dryness (also known as xerotrachea), a variety of interstitial lung diseases (ILDs), non-Hodgkin lymphomas, pleural thickening or effusion, and, rarely, thromboembolic disease or pulmonary hypertension [<a href="#rid1">1-3</a>].</p><p>The management and prognosis of interstitial lung disease in SjD will be reviewed here. The clinical manifestations, classification, evaluation, and diagnosis of Sjögren's disease and its associated interstitial lung diseases are presented separately. (See  <a class="medical medical_review" href="/d/html/5603.html" rel="external">"Diagnosis and classification of Sjögren’s disease"</a> and  <a class="medical medical_review" href="/d/html/4301.html" rel="external">"Interstitial lung disease associated with Sjögren's disease: Clinical manifestations, evaluation, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/14921.html" rel="external">"Overview of the management and prognosis of Sjögren's disease"</a> and  <a class="medical medical_review" href="/d/html/113735.html" rel="external">"Treatment of Sjögren's disease: Constitutional and non-sicca organ-based manifestations"</a>.)</p><p class="headingAnchor" id="H17660654"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Management strategies for Sjögren-associated lung diseases are empiric, since no controlled studies have been performed. We base the treatment approach on the identified lung pathology, and the severity of symptoms, physiologic impairment, and extent of radiographic disease. (See  <a class="medical medical_review" href="/d/html/4301.html" rel="external">"Interstitial lung disease associated with Sjögren's disease: Clinical manifestations, evaluation, and diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H17660661"><span class="h2">Sjögren-associated ILD without biopsy confirmation</span><span class="headingEndMark"> — </span>Asymptomatic patients with mild interstitial lung disease (ILD) based on high-resolution computed tomography (HRCT) and/or pulmonary function testing (PFTs) may prefer not to pursue a lung biopsy for histopathologic diagnosis. For these patients, we monitor symptoms, HRCT, and PFTs at 6- to 12-month intervals. If progressive disease is identified, we typically advise further evaluation to identify the radiologic pattern of the underlying ILD. (See  <a class="medical medical_review" href="/d/html/4301.html" rel="external">"Interstitial lung disease associated with Sjögren's disease: Clinical manifestations, evaluation, and diagnosis", section on 'Evaluation'</a>.)</p><p class="headingAnchor" id="H17660668"><span class="h2">Nonspecific interstitial pneumonia</span><span class="headingEndMark"> — </span>For asymptomatic patients with SjD-associated nonspecific interstitial pneumonia (NSIP) with normal or minimally abnormal PFTs, we suggest longitudinal clinical, functional, and radiological evaluation rather than active treatment, as some patients with NSIP can improve or stabilize without therapy. The majority of patients, though, are symptomatic and require therapy. (See  <a class="medical medical_review" href="/d/html/4306.html" rel="external">"Treatment and prognosis of nonspecific interstitial pneumonia", section on 'Overview of treatment'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial therapy </strong>– For symptomatic patients with SjD-associated NSIP who have worsening symptoms, PFTs, and radiographic abnormalities, we typically initiate treatment with oral glucocorticoids, although clinical trial data are lacking. <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">Prednisone</a> is usually started at a dose of 0.5 to 1 mg/kg ideal body weight up to a maximum of 60 mg per day [<a href="#rid4">4</a>]. This treatment is similar to that used for idiopathic NSIP and is supported by the results of reported case series, in which the specific type of ILD was not specified, but was most likely nonspecific interstitial pneumonia. In a series of five patients with a confirmed diagnosis of NSIP, four improved with prednisone at this dose [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/4306.html" rel="external">"Treatment and prognosis of nonspecific interstitial pneumonia", section on 'Glucocorticoids'</a>.)</p><p></p><p class="bulletIndent1">The response to therapy is assessed after four to six weeks with evaluation of symptoms and PFTs. For patients who respond to <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, we continue a low dose for at least six months, monitoring the response with interval clinical evaluations, pulmonary function tests, and HRCT scanning.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lack of improvement or intolerance of glucocorticoids</strong> – For patients who do not improve with systemic glucocorticoids or who improve, but develop side effects of therapy, immunosuppressive therapy may be beneficial.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Azathioprine</strong> – <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">Azathioprine</a> has been used with limited success in SjD-associated NSIP. As an example, a nonrandomized study found that 11 patients treated with azathioprine showed a significant improvement in forced vital capacity at six months when compared to untreated patients (p &lt;0.05) [<a href="#rid5">5</a>]. We typically follow the treatment approach outlined for using azathioprine in NSIP. (See  <a class="medical medical_review" href="/d/html/4306.html" rel="external">"Treatment and prognosis of nonspecific interstitial pneumonia", section on 'Azathioprine'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mycophenolate</strong><strong> mofetil</strong> – Small case series suggest that <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF) may be effective in connective tissue disease-associated ILD, although few data exist regarding SjD-ILD. In a series of 125 patients with connective tissue disease of which five had SjD, MMF was well-tolerated and had a glucocorticoid-sparing effect [<a href="#rid6">6</a>]. The use of MMF in the treatment of rheumatic disease is reviewed separately. (See  <a class="medical medical_review" href="/d/html/7990.html" rel="external">"Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory disease</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Rituximab</strong><strong> </strong>– The optimal role of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> in SjD-associated ILD is not known. A few case reports and case series have described improvement in SjD with rituximab treatment, but as the patients did not undergo lung biopsy, the exact histopathology is not known [<a href="#rid7">7</a>]. In one report, a patient with refractory pulmonary opacities, pleural effusion, and other systemic manifestations of primary Sjögren's disease (pSjD) responded to rituximab treatment with clearing of the lung manifestations [<a href="#rid8">8</a>]. In a review of the efficacy of rituximab in pSjD from a French Registry, among 78 pSjD patients, 9 had pSjD-related pulmonary involvement: one bronchiolar and eight ILD [<a href="#rid9">9</a>]. Six of the eight ILD patients responded to the first cycle of rituximab, as did the patient with bronchial involvement. Larger clinical trials are needed before rituximab is considered for routine use in SjD-associated ILD [<a href="#rid10">10</a>]. The use of rituximab in the management of rheumatic disease is discussed separately. (See  <a class="medical medical_review" href="/d/html/7501.html" rel="external">"Rituximab: Principles of use and adverse effects in rheumatoid arthritis"</a> and  <a class="medical medical_review" href="/d/html/113735.html" rel="external">"Treatment of Sjögren's disease: Constitutional and non-sicca organ-based manifestations", section on 'Rituximab'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other agents</strong> – <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">Cyclophosphamide</a> and <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> have been employed in limited numbers of patients with interstitial lung disease due to SjD that is resistant to glucocorticoids [<a href="#rid11">11-13</a>]. These agents carry substantial toxicity. Their use in the management of NSIP is discussed separately. (See  <a class="medical medical_review" href="/d/html/4306.html" rel="external">"Treatment and prognosis of nonspecific interstitial pneumonia", section on 'Cyclophosphamide'</a> and  <a class="medical medical_review" href="/d/html/4306.html" rel="external">"Treatment and prognosis of nonspecific interstitial pneumonia", section on 'Calcineurin inhibitors'</a>.)</p><p></p><p class="headingAnchor" id="H170246226"><span class="h2">Usual interstitial pneumonia</span><span class="headingEndMark"> — </span>The usual interstitial pneumonia (UIP) pattern is uncommon in patients with SjD, and formal study of treatment options is lacking. For patients with progressive fibrosing ILD who are unimproved after a trial of the above therapies, antifibrotic therapy, such as <a class="drug drug_general" data-topicid="97640" href="/d/drug information/97640.html" rel="external">nintedanib</a> (used in idiopathic pulmonary fibrosis [IPF]), may slow disease progression, based on results in other progressive fibrosing ILDs [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/d/html/4328.html" rel="external">"Treatment of idiopathic pulmonary fibrosis", section on 'Nintedanib'</a> and  <a class="medical medical_review" href="/d/html/4306.html" rel="external">"Treatment and prognosis of nonspecific interstitial pneumonia", section on 'Nintedanib'</a> and  <a class="medical medical_review" href="/d/html/4306.html" rel="external">"Treatment and prognosis of nonspecific interstitial pneumonia", section on 'Future directions'</a>.)</p><p class="headingAnchor" id="H17660675"><span class="h2">Lymphoid interstitial pneumonia</span><span class="headingEndMark"> — </span>Most patients with lymphoid interstitial pneumonia (LIP) associated with SjD are symptomatic and have evidence of physiologic impairment. No clinical trials have been performed, but our experience suggests that such patients respond well to oral glucocorticoids, although some require the addition of an alternate immunosuppressive agent. The management of LIP is discussed separately. (See  <a class="medical medical_review" href="/d/html/4361.html" rel="external">"Lymphoid interstitial pneumonia"</a> and  <a class="medical medical_review" href="/d/html/113735.html" rel="external">"Treatment of Sjögren's disease: Constitutional and non-sicca organ-based manifestations", section on 'Cardiopulmonary manifestations'</a>.)</p><p class="headingAnchor" id="H17660682"><span class="h2">Organizing pneumonia</span><span class="headingEndMark"> — </span>The treatment of organizing pneumonia associated with SjD follows that of cryptogenic organizing pneumonia and is discussed separately. The majority of patients are treated with an oral glucocorticoid at an initial dose equivalent to <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 1 mg/kg per day. (See  <a class="medical medical_review" href="/d/html/4332.html" rel="external">"Cryptogenic organizing pneumonia", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H17660689"><span class="h2">Follicular bronchiolitis</span><span class="headingEndMark"> — </span>The optimal treatment of follicular bronchiolitis complicating SjD is not known. Often, follicular bronchiolitis is found in association with NSIP, LIP, or organizing pneumonia in which case the treatment typically follows that of the associated ILD [<a href="#rid13">13</a>]. When follicular bronchiolitis complicates rheumatoid arthritis, treatment is aimed at the underlying rheumatoid arthritis. (See  <a class="medical medical_review" href="/d/html/4306.html" rel="external">"Treatment and prognosis of nonspecific interstitial pneumonia", section on 'Overview of treatment'</a> and  <a class="medical medical_review" href="/d/html/4361.html" rel="external">"Lymphoid interstitial pneumonia", section on 'Treatment'</a> and  <a class="medical medical_review" href="/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults"</a> and  <a class="medical medical_review" href="/d/html/4332.html" rel="external">"Cryptogenic organizing pneumonia", section on 'Treatment'</a>.)</p><p>For patients with minimal or no symptoms and no associated ILD, treatment is not indicated, as progressive disease is uncommon [<a href="#rid15">15</a>]. Instead, symptoms, pulmonary function, and HRCT are monitored at 6- to 12-month intervals. </p><p>For symptomatic patients with evidence of impairment on PFTs, we usually initiate treatment with an oral glucocorticoid. Successful treatment with oral glucocorticoids at a median initial dose of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 40 mg daily has been described [<a href="#rid15">15</a>]. A series of five SjD patients with severe bronchiolitis reported clinical and functional improvement with inhaled steroid, inhaled bronchodilators, and macrolides [<a href="#rid16">16</a>].</p><p>In a case series of patients with pSjD-associated lung disease, a patient who had bronchiolar involvement had a clinical response to <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid9">9</a>]. The use of rituximab in the management of SjD is discussed separately. (See <a class="local">'Nonspecific interstitial pneumonia'</a> above and  <a class="medical medical_review" href="/d/html/113735.html" rel="external">"Treatment of Sjögren's disease: Constitutional and non-sicca organ-based manifestations", section on 'Rituximab'</a>.)</p><p class="headingAnchor" id="H17660696"><span class="h2">Nodular lymphoid hyperplasia</span><span class="headingEndMark"> — </span>No specific treatment has been established for pulmonary nodular lymphoid hyperplasia in patients with SjD, and at least one patient has remained stable without specific therapy [<a href="#rid17">17</a>]. In addition, a few case reports and case series of nodular lymphoid hyperplasia not associated with SjD describe stability or regression [<a href="#rid18">18,19</a>]. However, others warn that lymphoma may develop in some patients thought to have nodular lymphoid hyperplasia either due to evolution of the process or the emergence of a small focus of lymphoma that was initially missed [<a href="#rid20">20</a>]. We typically monitor patients with a repeat CT scan at six-month intervals for the first year and then annually.</p><p class="headingAnchor" id="H17660703"><span class="h2">Lymphoma</span><span class="headingEndMark"> — </span>The evaluation and management of marginal zone lymphoma is discussed separately. (See  <a class="medical medical_review" href="/d/html/4710.html" rel="external">"Treatment of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT lymphoma)"</a> and  <a class="medical medical_review" href="/d/html/4733.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT)"</a>.)</p><p class="headingAnchor" id="H17660710"><span class="h2">Pulmonary nodular amyloidosis</span><span class="headingEndMark"> — </span>There are insufficient data to advise a particular management strategy for pulmonary nodular amyloidosis occurring in the absence of lymphoma, as only a few cases have been reported. Pulmonary nodular amyloidosis appears to remain stable or progress slowly without specific therapy; gradual enlargement of nodules and occasional cavitation are reported [<a href="#rid21">21-23</a>]. (See  <a class="medical medical_review" href="/d/html/131094.html" rel="external">"Pleuropulmonary manifestations of amyloidosis"</a> and  <a class="medical medical_review" href="/d/html/6666.html" rel="external">"Treatment and prognosis of immunoglobulin light chain (AL) amyloidosis"</a>.)</p><p class="headingAnchor" id="H17660717"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The natural history of the various lung diseases associated with SjD is not well-established. Some studies report a progressive reduction in diffusing capacity (DLCO) or forced vital capacity (FVC) over four years [<a href="#rid24">24,25</a>], but others describe a mixture of improvement (16 percent), stabilization (43 percent), and deterioration (37 percent) [<a href="#rid26">26</a>]. A separate 10-year follow-up of pulmonary function reported that many patients do not experience progressive lung disease and that diffusing capacity may improve independent of treatment [<a href="#rid27">27</a>]. </p><p>In a series of 85 patients with primary SjD, the development of interstitial lung disease (ILD) was associated with a trend towards poorer survival compared with those who did not have ILD (hazard ratio for death 2.16, 95% CI 0.99-4.74) [<a href="#rid28">28</a>]. In another study, patients with primary SjD and ILD (n = 33) the overall five-year survival rate was 87 percent [<a href="#rid29">29</a>]. The Norwegian systemic connective tissue disease (CTD) and vasculitis registry (NOSVAR), among 216 pSjD patients, found 59 (27 percent) with ILD, those patients had Physical Functioning subscore (SF-36) significantly reduced (P = 0.03) and a fourfold increased risk of dying after 10 years of disease (n = 10, 17 percent) compared with those without lung involvement (n = 7, 4.5 percent) (P = 0.002) [<a href="#rid30">30</a>].</p><p>Variances in the clinical course may reflect the type of lung disease and the severity of the underlying connective tissue disease. When looking individually at the types of ILD, the prognosis of nonspecific interstitial pneumonia, lymphoid interstitial pneumonia, and organizing pneumonia in the setting of SjD is generally favorable [<a href="#rid29">29,31</a>]. Adverse prognostic factors include purpura, decreased levels of C4 complement, mixed monoclonal cryoglobulinemia, pulmonary hypertension, and lymphoma [<a href="#rid29">29,31</a>]. Features associated with usual interstitial pneumonia, such as more extensive reticular changes on high-resolution computed tomography (HRCT) and a greater number of fibroblast foci on histologic examination, are associated with a worse prognosis [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H2079700176"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117117.html" rel="external">"Society guideline links: Sjögren's disease"</a> and  <a class="medical medical_society_guidelines" href="/d/html/118793.html" rel="external">"Society guideline links: Interstitial lung disease"</a>.)</p><p class="headingAnchor" id="H17661119"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>For asymptomatic patients with Sjögren's disease (SjD)-associated interstitial lung disease (ILD) without a specific histopathologic diagnosis, we monitor symptoms, high-resolution computed tomography (HRCT) and pulmonary function tests (PFTs) at 6- to 12-month intervals. (See <a class="local">'Sjögren-associated ILD without biopsy confirmation'</a> above and  <a class="medical medical_review" href="/d/html/4301.html" rel="external">"Interstitial lung disease associated with Sjögren's disease: Clinical manifestations, evaluation, and diagnosis", section on 'Lung biopsy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For asymptomatic patients with SjD-associated nonspecific interstitial pneumonia (NSIP) with normal or minimally abnormal PFTs, we suggest longitudinal clinical, functional, and radiological evaluation rather than active treatment (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Nonspecific interstitial pneumonia'</a> above.)</p><p></p><p class="bulletIndent1">For symptomatic patients with SjD-associated NSIP who have worsening symptoms, PFTs, and radiographic abnormalities, we suggest initiating treatment with oral glucocorticoids (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We typically use <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> at a dose of 1 mg/kg ideal body weight per day. Subsequent management is based on the response to therapy. (See <a class="local">'Nonspecific interstitial pneumonia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The usual interstitial pneumonia (UIP) pattern is uncommon in patients with SjD. The role of antifibrotic therapies, such as those used in idiopathic pulmonary fibrosis (IPF), remains unclear. (See <a class="local">'Usual interstitial pneumonia'</a> above and  <a class="medical medical_review" href="/d/html/4328.html" rel="external">"Treatment of idiopathic pulmonary fibrosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The management of SjD-associated lymphoid interstitial pneumonia (LIP) follows that for cryptogenic LIP and is discussed separately. (See  <a class="medical medical_review" href="/d/html/4361.html" rel="external">"Lymphoid interstitial pneumonia", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The treatment of organizing pneumonia associated with SjD follows that for cryptogenic organizing pneumonia and is discussed separately. (See  <a class="medical medical_review" href="/d/html/4332.html" rel="external">"Cryptogenic organizing pneumonia", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The optimal treatment of follicular bronchiolitis is not known. For patients with minimal or no symptoms and no associated ILD, we suggest observation rather than active therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For symptomatic patients with evidence of impairment on PFTs, we suggest initiating treatment with an inhaled steroid, bronchodilator and macrolide (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>), reserving oral glucocorticoid (<a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> at 40 mg daily) for more severe cases. When follicular bronchiolitis occurs in combination with NSIP, LIP, or OP, the treatment is directed at the ILD. (See <a class="local">'Follicular bronchiolitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with ILD or follicular bronchiolitis that is unresponsive to glucocorticoids and immunosuppressive agents (eg, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a>), <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> may be a therapeutic option. (See <a class="local">'Nonspecific interstitial pneumonia'</a> above and <a class="local">'Follicular bronchiolitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with pulmonary nodular lymphoid hyperplasia, we suggest observation with interval HRCTs to assess for development of lymphoma without specific treatment of the hyperplasia (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The evaluation and management of marginal zone lymphoma is discussed separately. (See  <a class="medical medical_review" href="/d/html/4710.html" rel="external">"Treatment of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT lymphoma)"</a> and  <a class="medical medical_review" href="/d/html/4733.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No specific therapy has been described for pulmonary nodular amyloidosis; the nodules appear to remain stable or enlarge slowly without specific therapy. (See <a class="local">'Pulmonary nodular amyloidosis'</a> above.)</p><p></p><p class="headingAnchor" id="H2509238013"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Daniel Deheinzelin, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Gupta S, Ferrada MA, Hasni SA. Pulmonary Manifestations of Primary Sjögren's Syndrome: Underlying Immunological Mechanisms, Clinical Presentation, and Management. Front Immunol 2019; 10:1327.</a></li><li><a class="nounderline abstract_t">Luppi F, Sebastiani M, Sverzellati N, et al. Lung complications of Sjogren syndrome. Eur Respir Rev 2020; 29.</a></li><li><a class="nounderline abstract_t">Lee AS, Scofield RH, Hammitt KM, et al. Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren's. Chest 2021; 159:683.</a></li><li><a class="nounderline abstract_t">Parambil JG, Myers JL, Lindell RM, et al. Interstitial lung disease in primary Sjögren syndrome. Chest 2006; 130:1489.</a></li><li><a class="nounderline abstract_t">Deheinzelin D, Capelozzi VL, Kairalla RA, et al. Interstitial lung disease in primary Sjögren's syndrome. Clinical-pathological evaluation and response to treatment. Am J Respir Crit Care Med 1996; 154:794.</a></li><li><a class="nounderline abstract_t">Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 2013; 40:640.</a></li><li><a class="nounderline abstract_t">Isaksen K, Jonsson R, Omdal R. Anti-CD20 treatment in primary Sjögren's syndrome. Scand J Immunol 2008; 68:554.</a></li><li><a class="nounderline abstract_t">Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis 2007; 66:351.</a></li><li><a class="nounderline abstract_t">Gottenberg JE, Cinquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis 2013; 72:1026.</a></li><li><a class="nounderline abstract_t">Ramos-Casals M, Tzioufas AG, Stone JH, et al. Treatment of primary Sjögren syndrome: a systematic review. JAMA 2010; 304:452.</a></li><li><a class="nounderline abstract_t">Hansen LA, Prakash UB, Colby TV. Pulmonary lymphoma in Sjögren's syndrome. Mayo Clin Proc 1989; 64:920.</a></li><li><a class="nounderline abstract_t">Deheinzelin D, de Carvalho CR, Tomazini ME, et al. Association of Sjögren's syndrome and sarcoidosis. Report of a case. Sarcoidosis 1988; 5:68.</a></li><li><a class="nounderline abstract_t">Shi JH, Liu HR, Xu WB, et al. Pulmonary manifestations of Sjögren's syndrome. Respiration 2009; 78:377.</a></li><li><a class="nounderline abstract_t">Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med 2019; 381:1718.</a></li><li><a class="nounderline abstract_t">Aerni MR, Vassallo R, Myers JL, et al. Follicular bronchiolitis in surgical lung biopsies: clinical implications in 12 patients. Respir Med 2008; 102:307.</a></li><li><a class="nounderline abstract_t">Borie R, Schneider S, Debray MP, et al. Severe chronic bronchiolitis as the presenting feature of primary Sjögren's syndrome. Respir Med 2011; 105:130.</a></li><li><a class="nounderline abstract_t">Song MK, Seol YM, Park YE, et al. Pulmonary nodular lymphoid hyperplasia associated with Sjögren's syndrome. Korean J Intern Med 2007; 22:192.</a></li><li><a class="nounderline abstract_t">Miyoshi S, Hamada H, Katayama H, et al. A case of pulmonary nodular lymphoid hyperplasia with a resected cavity, followed by spontaneous regression of the remaining lesions. Intern Med 2010; 49:1617.</a></li><li><a class="nounderline abstract_t">Abbondanzo SL, Rush W, Bijwaard KE, Koss MN. Nodular lymphoid hyperplasia of the lung: a clinicopathologic study of 14 cases. Am J Surg Pathol 2000; 24:587.</a></li><li><a class="nounderline abstract_t">Travis WD, Galvin JR. Non-neoplastic pulmonary lymphoid lesions. Thorax 2001; 56:964.</a></li><li><a class="nounderline abstract_t">Rajagopala S, Singh N, Gupta K, Gupta D. Pulmonary amyloidosis in Sjogren's syndrome: a case report and systematic review of the literature. Respirology 2010; 15:860.</a></li><li><a class="nounderline abstract_t">Suzuki H, Matsui K, Hirashima T, et al. Three cases of the nodular pulmonary amyloidosis with a longterm observation. Intern Med 2006; 45:283.</a></li><li><a class="nounderline abstract_t">Berk JL, O'Regan A, Skinner M. Pulmonary and tracheobronchial amyloidosis. Semin Respir Crit Care Med 2002; 23:155.</a></li><li><a class="nounderline abstract_t">Linstow M, Kriegbaum NJ, Backer V, et al. A follow-up study of pulmonary function in patients with primary Sjögren's syndrome. Rheumatol Int 1990; 10:47.</a></li><li><a class="nounderline abstract_t">Mialon P, Barthélémy L, Sébert P, et al. A longitudinal study of lung impairment in patients with primary Sjögren's syndrome. Clin Exp Rheumatol 1997; 15:349.</a></li><li><a class="nounderline abstract_t">Roca F, Dominique S, Schmidt J, et al. Interstitial lung disease in primary Sjögren's syndrome. Autoimmun Rev 2017; 16:48.</a></li><li><a class="nounderline abstract_t">Davidson BK, Kelly CA, Griffiths ID. Ten year follow up of pulmonary function in patients with primary Sjögren's syndrome. Ann Rheum Dis 2000; 59:709.</a></li><li><a class="nounderline abstract_t">Nannini C, Jebakumar AJ, Crowson CS, et al. Primary Sjogren's syndrome 1976-2005 and associated interstitial lung disease: a population-based study of incidence and mortality. BMJ Open 2013; 3:e003569.</a></li><li><a class="nounderline abstract_t">Enomoto Y, Takemura T, Hagiwara E, et al. Prognostic factors in interstitial lung disease associated with primary Sjögren's syndrome: a retrospective analysis of 33 pathologically-proven cases. PLoS One 2013; 8:e73774.</a></li><li><a class="nounderline abstract_t">Palm O, Garen T, Berge Enger T, et al. Clinical pulmonary involvement in primary Sjogren's syndrome: prevalence, quality of life and mortality--a retrospective study based on registry data. Rheumatology (Oxford) 2013; 52:173.</a></li><li><a class="nounderline abstract_t">Kokosi M, Riemer EC, Highland KB. Pulmonary involvement in Sjögren syndrome. Clin Chest Med 2010; 31:489.</a></li></ol></div><div id="topicVersionRevision">Topic 15921 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31249572" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pulmonary Manifestations of Primary Sjögren's Syndrome: Underlying Immunological Mechanisms, Clinical Presentation, and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32817113" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Lung complications of Sjogren syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33075377" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren's.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17099028" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Interstitial lung disease in primary Sjögren syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8810621" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Interstitial lung disease in primary Sjögren's syndrome. Clinical-pathological evaluation and response to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23457378" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19000095" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Anti-CD20 treatment in primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16950808" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23264337" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20664046" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Treatment of primary Sjögren syndrome: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2796402" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pulmonary lymphoma in Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3381023" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Association of Sjögren's syndrome and sarcoidosis. Report of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19390161" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pulmonary manifestations of Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31566307" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17997299" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Follicular bronchiolitis in surgical lung biopsies: clinical implications in 12 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21050739" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Severe chronic bronchiolitis as the presenting feature of primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17939337" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pulmonary nodular lymphoid hyperplasia associated with Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20686301" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A case of pulmonary nodular lymphoid hyperplasia with a resected cavity, followed by spontaneous regression of the remaining lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10757408" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Nodular lymphoid hyperplasia of the lung: a clinicopathologic study of 14 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11713361" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Non-neoplastic pulmonary lymphoid lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20546191" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pulmonary amyloidosis in Sjogren's syndrome: a case report and systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16595995" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Three cases of the nodular pulmonary amyloidosis with a longterm observation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16088608" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pulmonary and tracheobronchial amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2349433" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A follow-up study of pulmonary function in patients with primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9272293" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A longitudinal study of lung impairment in patients with primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27682894" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Interstitial lung disease in primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10976085" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Ten year follow up of pulmonary function in patients with primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24282246" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Primary Sjogren's syndrome 1976-2005 and associated interstitial lung disease: a population-based study of incidence and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24040065" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Prognostic factors in interstitial lung disease associated with primary Sjögren's syndrome: a retrospective analysis of 33 pathologically-proven cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23192906" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical pulmonary involvement in primary Sjogren's syndrome: prevalence, quality of life and mortality--a retrospective study based on registry data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20692541" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pulmonary involvement in Sjögren syndrome.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
